Background: Patients with natural killer (NK) cell neoplasms, aggressive NK cell leukemia (ANKL) and extranodal NK cell lymphoma, nasal type (ENKL), have poor outcome. Both diseases show a spectrum and the boundary of them remains unclear. The purpose of this study is to draw a prognostic model of total NK cell neoplasms.
Epstein-Barr virus (EBV) is found in the tumor cells in virtually all cases, and therefore ENKL is now regarded as one of the EBV-related neoplasms [14, 15] .
ANKL has been recognized as a subtype of large granular lymphocyte (LGL) leukemia [16] [17] [18] and is now regarded as a distinct subtype in the WHO Classification [5] . Because of its rarity, ANKL had not been fully characterized until recently. This leukemia is characterized by systemic proliferation of NK cells, with an immunophenotype of surface CD32 CD2+ CD16+ CD56+ and germline configuration of T-cell receptor (TCR) genes. Its clinical course is highly aggressive, and most patients die within 2 years, many of them within 6 months after diagnosis [18] .
For ENKL, several Asian investigators reported clinical and prognostic characteristics in a relatively large number of patients [19] [20] [21] . These reports clearly demonstrated that >80% of ENKL presents with localized disease, and the International Prognostic Index (IPI) score is a good indicator for prognosis. However, all the reports excluded ANKL from their analyses and did not mention the relationship of ENKL and ANKL. In addition to IPI, other novel prognostic factors have been identified by Korean groups: local tumor invasiveness (LTI) [20] and regional lymph 
patients and methods diagnosis
The diagnosis of ENKL was made according to both histologic and immunophenotypic characteristics as described in the WHO Classification of 'Tumours of Haematopoietic and Lymphoid Tissues' [4, 5] . Patients were diagnosed with ENKL when the tumor cells from the biopsy specimen showed infiltration of pleomorphic tumor cells with cytoplasmic CD3+ and CD56+ phenotype and the presence of EBV. Several exceptional cases that lacked only one immunophenotypic marker or EBV but were also accompanied by other typical ENKL features were included for analysis. These atypical cases required germline configuration of TCR genes. For patients with typical phenotype, TCR studies were not mandatory. Angiocentricity and necrosis were not required for diagnosis but were used to help diagnosis. Those transformed from chronic active EBV lymphoproliferative disorder or chronic NK cell lymphocytosis were excluded, as were those diagnosed with blastic NK cell lymphoma (precursor NK cell lymphoblastic leukemia/lymphoma and blastic plasmacytoid dendritic cell neoplasm) [22] or any other types of T-cell lymphoma.
The diagnosis of ANKL was made as previously described [18] . Briefly, patients were diagnosed with ANKL when a proliferation of LGLs of NK cell phenotype was found in the peripheral blood (PB) and/or bone marrow (BM) exceeding 30% of the total nuclear cells. To exclude T-cell type LGL leukemia and leukemic infiltration of other T-cell lymphomas, the tumor cells were required to be negative for surface CD3 as determined by flow cytometry or germline configurations of TCR genes. The presence of EBV was determined with either in situ hybridization with an Epstein-Barrencoded RNA probe or with Southern blotting but was not required for the diagnosis. Complete response (CR) is defined as complete disappearance of tumors and all objective signs of disease lasting at least 4 weeks. Partial response (PR) decrease at least 50% reduction of the tumor at least 4 weeks without occurrence of new lesions. ANKLs) were included in this study. Detailed clinicopathologic characteristics of 22 ANKLs were described previously [18] . This study was conducted by the NK-cell Tumor Study Group and approved by the institutional review board of participating institutions. Initial diagnosis was made at each institution and was revised when the original histologic material was available. Specimens were reviewed by two expert hematopathologists (SN and JS) and clinical data were reviewed by the Diagnostic Committee (RS, KK and KO) as described previously [23] .
histologic and immunophenotypic examination
Histopathologic examination was conducted on formalin-fixed and paraffinembedded sections of tissue after staining with hematoxylin-eosin.
Immunohistochemical studies for various antigens and in situ hybridization for EBV-encoded RNA was carried out as described [24] . Briefly, the expression of antigens in the paraffin-embedded sections was examined by using the avidin-biotin complex peroxidase method. The antibodies comprised CD3 (Dako; Santa Fe, CA), CD56 (Novocastra Laboratories; Newcastle, UK), L26/CD20 (Dako), CD79a (Dako), UCHL1/CD45RO (Dako), MT1/CD43 (Bio-Science Products; Emmenbrucke, Switzerland), CD4 (Novocastra), CD8 (Dako), E29/EMA (Coulter Immunology; Hialeah, FL), Leu7/CD57 (Becton-Dickinson; Sunnyvale, CA), LMP-1 (Dako), DO-7/p53 (Dako), bcl-2 (Dako), TIA-1 (Coulter Immunology) and granzyme B (Monosan; Uden, The Netherlands). Flow cytometric immunophenotyping including cytoplasmic CD3 (cyCD3) was carried out, as described previously [25] . For CD16 antibody, Leu11 (Becton-Dickinson; Franklin Lakes, NJ) and ION16 (Beckman Coulter; Fullerton, CA) were used.
statistical analysis
The LDH index was calculated at each of the institutes from a patient's serum LDH level divided by the upper limit of serum LDH. IPI and prognostic index for T-cell lymphoma (PIT) scores were calculated as previously described [26, 27] . The treatment response was assessed according to standard response criteria [28] . results
patient characteristics
The characteristics of 172 patients are listed in Table 1 . Of the 150 ENKLs, 123 presented with nasal and/or paranasal lesions, which were categorized as nasal NK cell lymphoma in the following analyses. Remaining 27 did not show any nasal/ paranasal involvements by physical examination and computer tomography and were categorized as extranasal NK cell lymphoma. The origin of these cases was the skin in 16 subjects, the liver and/or spleen in 10, and the intestine in 1. ANKL showed significantly younger age onset than ENKL (median: 42 versus 53 years, P = 0.04). Nasal ENKL showed male predominance (male : female, 81 : 42), but extranasal ENKL (12 : 15) and ANKL (7 : 15) did not (P = 0.003). Among ENKL cases, those originating from the nasal region showed a higher percentage of localized disease (stage I) than those from extranasal sites (45% versus 22%, P = 0.03). The former showed a significantly lower distribution of the clinical stage than the latter (P = 0.002). The presence of B symptoms was high in extranasal ENKL and ANKL but low in nasal ENKL (P = 0.004). The performance status of patients with extranasal origin was significantly worse than that of patients with nasal origin (P = 0.01). All but one case showed extranodal involvement at initial presentation. Of the 123 cases of nasal NK cell lymphoma, 111 presented with involvement of the nasal/paranasal sinus, 28 with the pharynx/oral cavity and 16 with both. Only one case presented with systemic lymph node involvement. Distributions of all three prognostic indexes were significantly lower for the nasal ENKL group.
immunophenotype
Results of immunophenotyping are summarized in Table 2 .
Most cases of each type were positive for CD2, CD56, human leukocyte antigen-DR, TIA-1 and granzyme B, indicating their NK cell origin. CD7, CD8, CD16, CD57 and cyCD3 were positive in varying degrees. Those examined were proved to be uniformly negative for T-(CD1, CD3, CD4, CD5 and TCRs), B-(CD10, CD19, CD20 and CD79) and myelomonocytic markers (CD13, CD14, CD15 and CD33), as well as for CD25 and CD34. The expression of cyCD3 was significantly higher for ENKL (82% versus 43%, P = 0.009) but that of CD16 was lower (22% versus 75%, P < 0.001) than for ANKL. EpsteinBarr virus was also detected in most of the cases.
therapy and clinical course
Of 55 patients with stage I nasal ENKL, 17 received radiotherapy first and 35 chemotherapy first. Eleven of the former were further treated with supplemental chemotherapy, and 18 of the latter received additional radiotherapy. One patient was treated with simultaneous chemoradiotherapy, but two could not be treated due to their poor condition. Twenty-five patients received hematopoietic stem-cell transplantations (HSCTs; 17 autografts and 8 allografts), which were described previously [29, 30] . For stage I patients, complete response (CR) rate was 73%, and the response rate was 82% (Table 3) . Although no statistical superiority was found, the CR rate exceeded 80% for patients who received radiotherapy first. In contrast, the CR rates for patients treated with chemotherapy alone and those with chemotherapy followed by radiotherapy were 65% and 72%, respectively. All but three patients with stage II disease received chemotherapy. Two of the patients received radiotherapy, but one could not receive any therapy due to the poor condition. Each two of the patients with stage III and IV disease could not also receive any therapy, but the others were treated with various types of combination chemotherapy. The CR rate was significantly different by the clinical stage (39% in stage II, 56% in stage III and 15% in stage IV). No significant differences in response rates were found between nasal and extranasal ENKLs when stratified by clinical stage. The CR and response rates of stage IV patients were comparable with those of ANKL.
difference between ANKL and ENKL
The OS curves of nasal and extranasal ENKL and ANKL are shown in Figure 1A . Prognosis was significantly different original article Annals of Oncology among the three disease categories (P < 0.0001). The OS curves of nasal and extranasal ENKL with different clinical stages are shown in Figure 1B and C, respectively. Prognosis was significantly different according to the clinical stage (P < 0.0001), but stage III group showed better prognosis than stage II group. If restricted to patients with stage IV diseases, the prognosis was equally poor for all disease subtypes ( Figure  1D , P = 0.16). Due to this result and the similar CR rates between ANKL and stage IV ENKL noted above, we compared the clinicopathologic characteristics of ANKL and stage IV ENKL (supplemental Table S1 , available at Annals of Oncology online). Although differences in age of onset, presence of B symptoms, performance status and IPI vanished when restricted to stage IV cases, sex distribution and phenotypic markers (CD16 and cyCD3) were still significantly different. For stage IV ENKL cases, male : female ratio was 31 : 16, and CD16 and cyCD3 were positive in 5 of 18 (28%) and 27 of 33 cases (82%), respectively.
prognostic factors and model
Although patient age was not a significant prognostic factor, univariate Cox analysis identified the following prognostic factors: clinical stage, performance status, number of extranodal involvements, serum LDH index, presence of B symptoms, BM involvement, regional lymph node involvement, disease type and white blood cell count (Table 4 and supplemental Figure S1 , available at Annals of Oncology online). IPI category, PIT and Korean index were also highly prognostic (Figures 2 and 3 ). Multivariate analysis revealed four factors, advanced stage (III or IV), poor Eastern Cooperative Oncology Group performance status (2-4), extranodal involvement (more than one) and disease type (extranasal/aggressive), to be significant and independent prognostic factors ( Table 4) . All patients were then scored according to these four factors. Fifty-eight patients did not have any of the factors, 29 had one factor, 37 had two factors, 29 had Annals of Oncology original article three factors and 18 had all four factors. The OS curves according to the new NK cell tumor prognostic index are shown in Figure 4 . The new index categorized four groups with significantly different prognoses. Four-year OS rate was 48% for patients with score 0 or 1 and 11% for those with score 2-4 ( Figure 4A , P < 0.0001). Four-year OS rates were 55%, 33%, 15% and 6% for patients with score 0, score 1, score 2 and score 3 or 4, respectively ( Figure 4B , P < 0.0001).
discussion
Since the recognition of ENKL and ANKL 20 years ago, precise comparisons have not yet been satisfactorily conducted.
Although the clinicopathologic characteristics of nasal NK cell lymphoma and ANKL are very different, the immunophenotypic profiles, genotype (germline TCR genes) and the close association with EBV are quite similar. Particularly, ENKL of extranasal origin shows high incidence of BM involvement and aggressive clinical course [31] [32] [33] [34] [35] [36] . On the other hand, ANKL is characterized by a predilection to hepatosplenic involvement, indicating the existence of a spectrum between these two diseases [37] . However, our analysis showed discrete differences for the age of onset and expression of CD16. Although difference in cyCD3 expression was recognized, only a few numbers of cases were examined.
The difference of cyCD3 expression should be examined in a large number of cases. For extranasal NK cell lymphomas, the skin was the most common site of involvement but not for ANKL. Considered together with the difference in genomic gain/loss profiles [38, 39] , ANKL and ENKL are concluded to be different in several disease features. However, no specific genes or regions have been identified to separate these two diseases. We tentatively set the boundary of ANKL and ENKL as 30% of BM/PB involvement because this is the most objective criterion [18] . If this differentiation is not generalized, the boundary of ANKL and ENKL can be ambiguous. Further investigations are needed to identify the biological differences between the two diseases. For the consideration of clinical management, therapeutic responses and prognoses of ANKL and stage IV ENKL are similarly poor, indicating that both diseases should be treated equally. Long-term survival of stage I cases from our series was 40%. This is consistent with other studies for NK cell lymphoma in the literature [40] [41] [42] [43] but lower than that of other lymphoma subtypes [44] . One reason for the poor prognosis of this lymphoma is the expression of P-glycoprotein, which mediates multidrug resistance [45, 46] . Therefore, radiotherapy plays a key role in the treatment of this lymphoma. We compared response rates and prognoses with the initial therapeutic strategy. Patients who were treated with radiotherapy followed by chemotherapy showed the most original article Annals of Oncology favorable response and prognosis, but the differences were not statistically significant. Currently, involved-field radiotherapy followed by chemotherapy is still regarded as a standard treatment of early-stage diseases [47] . Simultaneous chemoradiotherapy is now under evaluation by a Japanese group [48] .
For advanced-stage cases, although long-term survival after high-dose chemotherapy and HSCT has been reported [29, [49] [50] [51] , no standard chemotherapy is currently available [52] . Because L-asparaginase has been reported to be effective in several patients with NK/T-cell lymphoma [53] [54] [55] , we recently conducted a phase I study of combination chemotherapy including L-asparaginase [56] . The SMILE regimen comprises a steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase and etoposide. Methotrexate, ifosfamide and L-asparaginase are multidrug resistanceunrelated agents and etoposide shows both in vitro and in vivo efficacy for EBV-associated lymphoproliferative disorders. Level 1 SMILE was feasible and the overall response rate was 67% [56] . The SMILE regimen is a promising combination chemotherapy for advanced stage of ENKL and ANKL.
The current study identified that the IPI category was also prognostic for extranodal NK/T-cell lymphoma, which is consistent with other studies in the literature [19] [20] [21] . However, regarding the IPI components, only age was not prognostic, in contrast to other factors (clinical stage, serum LDH level, performance status and number of extranodal sites). Absence of age as a prognostic factor is consistent with the Korean study, which included the largest number of patients [21] . The Korean study also identified a novel prognostic index including B symptoms, clinical stage, serum LDH level and regional lymph node involvement. This Korean index [21] , as well as the PIT category [27] , was also prognostic for our series of patients, but multivariate analysis identified another combination of factors that was the most prognostic for patients of the current study. Another Korean group pointed out LTI as a significant prognostic factor [20] . In our patients, however, LTI was only recognized in a limited population, and therefore, LTI was not a significant prognostic factor. Notably, in our series, extranasal onset of disease has been identified as one of the significant prognostic factors. For ENKL, the difference between nasal and extranasal origin is a focus of interest in the recently published result of International Peripheral T/NK cell Lymphoma Project [57, 58] . Further investigations are needed to identify the appropriate prognostic model for extranodal NK cell lymphoma and leukemia.
In conclusion, stage IV ENKL and ANKL are different in several clinicopathologic features but show similar therapeutic response and prognosis. Our novel NK prognostic index is useful for improving treatment choices and designing clinical trials to evaluate new treatment strategies.
